GlassScriptPhysician profile
Thomas J Abbenante
NPI 1821232034
$3,052.10
in general payments reported to CMS, 2019-2025
23 companies · $1,082 in 2025
The $1,082 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $310 · 2020: $22.92 · 2021: $193 · 2022: $116 · 2023: $110 · 2024: $1,217 · 2025: $1,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,281 · Travel and Lodging: $1,030 · Education: $98.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,281.49 |
| Travel and Lodging | $1,029.54 |
| Education | $98.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,501.20 | 2023-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $281.53 | 2019-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $264.30 | 2024-2025 | Lumryz |
| Uswm, LLC | $239.08 | 2021-2022 | |
| Indivior INC. | $120.46 | 2019-2025 | Sublocade |
| Resmed Corp | $98.88 | 2024 | |
| Harmony Biosciences LLC | $97.44 | 2022-2024 | |
| Zoll Respicardia, INC. | $93.90 | 2024 | Remede System |
| Astrazeneca Pharmaceuticals LP | $56.18 | 2023-2025 | Tezspire, Breztri |
| Alkermes, INC. | $43.35 | 2023-2025 | Vivitrol, Vivitrol |
| Amgen INC. | $30.79 | 2023-2024 | Tezspire |
| 3b Medical, INC. | $29.93 | 2025 | Luna |
| Insmed, INC. | $24.95 | 2024 | Arikayce |
| Vanda Pharmaceuticals INC. | $22.92 | 2020 | |
| Philips North America LLC | $20.38 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $19.59 | 2024 | Glassia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.53 | 2019 | |
| Lilly USA, LLC | $16.86 | 2025 | Zepbound |
| Electromed, INC. | $16.04 | 2019 | |
| Glaxosmithkline, LLC. | $15.47 | 2024 | Trelegy Ellipta |
| Abbvie INC. | $15.07 | 2024 | |
| Braeburn INC. | $13.40 | 2024 | Brixadi |
| Merck Sharp & Dohme LLC | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Abbenante listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.